ArticleClinical transplantation2020
Sex differences in eligibility for advanced heart failure therapies.
Article in Clinical transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Sex-based Differences in the Utility and Outcomes of Left Ventricular Assist Devices.Journal of the Saudi Heart Association · 2025Review
- Association of Psychosocial Risk Factors With Quality of Life and Readmissions 1 Year After LVAD Implantation.Journal of cardiac failure · 2025Article
- Sex and Gender-related Disparities in Clinical Characteristics and Outcomes in Heart Transplantation.Current heart failure reports · 2024Review
- Advanced Heart Failure Characteristics and Outcomes in Women and Men.Journal of the American Heart Association · 2024Article
- Sex Differences in Cardiac Transplantation.Current atherosclerosis reports · 2023Review
- Sex-Associated Differences in the Clinical Outcomes of Left Ventricular Assist Device Recipients: Insights From Interagency Registry for Mechanically Assisted Circulatory Support.Circulation. Heart failure · 2023Article
- Group Dynamics and Allocation of Advanced Heart Failure Therapies-Heart Transplants and Ventricular Assist Devices-By Gender, Racial, and Ethnic Group.Journal of the American Heart Association · 2023Article
- In Silico Studies and Design of Scrupulous Novel Sensor for Nitro Aromatics Compounds and Metal Ions Detection.Journal of fluorescence · 2022Article
- A scoping review of inequities in access to organ transplant in the United States.International journal for equity in health · 2022Article
- Association of race and gender with primary caregiver relationships and eligibility for advanced heart failure therapies.Clinical transplantation · 2022Article
- Special Considerations in the Care of Women With Advanced Heart Failure.Frontiers in cardiovascular medicine · 2022Review
- Sex-based considerations for implementation of ventricular assist device therapy.Frontiers in cardiovascular medicine · 2022Review
- Creation and Validation of a Novel Sex-Specific Mortality Risk Score in LVAD Recipients.Journal of the American Heart Association · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesWe investigated sex-based differences in eligibility for and outcomes after receipt of advanced heart failure (HF) therapies.
backgroundAlthough women are more likely to die from HF than men, registry data suggest that women are less likely to receive heart transplant (HT) or left ventricular assist device (LVAD) for largely unknown reasons.
methodsWe performed a single-center retrospective cohort study of patients evaluated for advanced HF therapies from 2012 to 2016. Logistic regression was used to determine the association of sex with eligibility for HT/LVAD. Competing risks and Kaplan-Meier analysis were used to examine survival.
resultsOf 569 patients (31% women) evaluated, 223 (39.2%) were listed for HT and 81 (14.2%) received destination (DT) LVAD. Women were less likely to be listed for HT (adjusted odds ratio [OR] 0.36, 95% confidence interval [CI] 0.21-0.61; P < .0001), based on allosensitization (P < .0001) and obesity (P = .02). Women were more likely to receive DT LVAD (adjusted OR 2.29, 95% CI 1.23-4.29; P = .01). Survival was similar between men and women regardless of whether they received HT and DT LVAD or were ineligible for therapy.
conclusionWomen are less likely to be HT candidates, but more likely to receive DT LVAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.